Vifor Pharma and Fresenius Kabi create JV in China

20 February 2020

Swiss drugmaker Vifor Pharma (VTX: VIFN) today said it has entered into strategic partnership with Germany-headquartered Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the second largest pharmaceutical market in the world.

The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. The latter will be fully responsible for the commercialization of the intravenous iron portfolio in China, covering more than 20,000 anesthesiologists and 25,000 surgeons in more than 2,000 tier 3 hospitals to support PBM as well as working with HCPs for other indications including nephrology.

There is a high unmet medical need for Vifor’s intravenous iron products in China with the country having the world’s largest iron deficiency anemia (IDA) population with prevalence estimated at 20%.

The strategic partnership also expands Vifor Pharma’s cooperation with the Fresenius Group, as Vifor Fresenius Medical Care Renal Pharma is an already existing joint company with Fresenius Medical Care.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK